<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02163434</url>
  </required_header>
  <id_info>
    <org_study_id>496486-3</org_study_id>
    <secondary_id>1R01HD076313-01A1</secondary_id>
    <nct_id>NCT02163434</nct_id>
  </id_info>
  <brief_title>Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum</brief_title>
  <official_title>Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University at Buffalo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will compare the effectiveness of gabapentin to metoclopramide for 1 week&#xD;
      among 60 women with hyperemesis gravidarum (HG) in this randomized, double-blinded trial.&#xD;
      After completion of the 1-week double-blind phase, subjects will be offered open-label&#xD;
      gabapentin with rescue metoclopramide until their symptoms no longer require treatment.&#xD;
      Enrollment will occur at the University's at Buffalo, of Rochester and of Wisconsin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">November 2019</completion_date>
  <primary_completion_date type="Actual">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline Adjusted Mean Daily Motherisk-PUQE Total Scores (Pregnancy-unique Quantification of Emesis and Nausea Scale) for Days 5-7</measure>
    <time_frame>1 week</time_frame>
    <description>Score range: 6-30 with higher score indicating a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline Adjusted Mean Daily Nausea Scores From the Motherisk-PUQE for Days 5-7.</measure>
    <time_frame>1 week</time_frame>
    <description>Score range: 2-10 with higher score indicating a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Adjusted Mean Daily Oral Nutrition Score for Days 5-7</measure>
    <time_frame>1 week</time_frame>
    <description>Score range: 0-15 with higher score indicating a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects Requiring Repeat iv Hydration or Hospital Admission for HG From the Outpatient Setting.</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Satisfaction of Treatment at the Study Endpoint.</measure>
    <time_frame>1 week</time_frame>
    <description>Score range: 0-4 with higher score indicating a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desire to Continue Therapy at Study Endpoint</measure>
    <time_frame>1 week</time_frame>
    <description>Scores: 0=no, 1=yes. Thus, a higher score indicates a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Hyperemesis Gravidarum</condition>
  <arm_group>
    <arm_group_label>gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1800-2400mg/day divided tid or qid, orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metoclopramide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45-60mg/day divided tid or qid, orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <arm_group_label>gabapentin</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide</intervention_name>
    <arm_group_label>metoclopramide</arm_group_label>
    <other_name>Reglan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have received at least 2 administrations of intravenous (iv) hydration separated by at&#xD;
             least 1 week or daily emesis for at least the last 14 days and 1 administration of iv&#xD;
             hydration.&#xD;
&#xD;
          2. Have at least one of the following: 2-4+ ketonuria, serum potassium &lt; 3.4mmol, or &gt;5%&#xD;
             weight loss from weight upon entry to prenatal care.&#xD;
&#xD;
          3. Have failed therapy with at least one antiemetic.&#xD;
&#xD;
          4. Have fetal ultrasound within 6 weeks prior to enrollment confirming a&#xD;
             normal-appearing, intrauterine, singleton pregnancy of gestational age &lt; 16 weeks at&#xD;
             time of enrollment.&#xD;
&#xD;
          5. Felt by the patient's obstetrician or emergency room attending physician not to have&#xD;
             other medical problems such as bowel obstruction, pancreatitis, biliary colic, or&#xD;
             peptic ulcer disease that could be contributing to the patient's symptoms.&#xD;
&#xD;
          6. Be &gt;18 years old and not decided to terminate the pregnancy.&#xD;
&#xD;
          7. Have not received or planning to receive a peripherally inserted central catheter (PIC&#xD;
             line).&#xD;
&#xD;
          8. Have a Motherisk-PUQE score of â‰¥12 for the 24-hour Baseline period.&#xD;
&#xD;
          9. Felt not to have any other significant medical, psychiatric or substance abuse problem&#xD;
             that would preclude participation in the study.&#xD;
&#xD;
         10. Denies drinking any alcohol after learning about current pregnancy.&#xD;
&#xD;
         11. Agrees to discontinue any current anti-emetic treatments (including antihistamines,&#xD;
             ginger, &gt; 10mg/day vitamin B6, serotonin or dopamine antagonists, anticholinergics,&#xD;
             acupuncture, hypnosis, or wrist bands) for the next 4 weeks.&#xD;
&#xD;
         12. Pregnancy not conceived through in-vitro fertilization.&#xD;
&#xD;
         13. Able to understand and comply with the study procedures and give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        None not mentioned under Inclusion Criteria.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Guttuso T Jr, Robinson LK, Amankwah KS. Gabapentin use in hyperemesis gravidarum: a pilot study. Early Hum Dev. 2010 Jan;86(1):65-6. doi: 10.1016/j.earlhumdev.2009.11.003. Epub 2009 Dec 16.</citation>
    <PMID>20015600</PMID>
  </reference>
  <reference>
    <citation>Holmes LB, Hernandez-Diaz S. Newer anticonvulsants: lamotrigine, topiramate and gabapentin. Birth Defects Res A Clin Mol Teratol. 2012 Aug;94(8):599-606. doi: 10.1002/bdra.23028. Epub 2012 Jun 22.</citation>
    <PMID>22730257</PMID>
  </reference>
  <reference>
    <citation>Guttuso T Jr. Gabapentin's anti-nausea and anti-emetic effects: a review. Exp Brain Res. 2014 Aug;232(8):2535-9. doi: 10.1007/s00221-014-3905-1. Epub 2014 Mar 26. Review.</citation>
    <PMID>24668130</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 9, 2014</study_first_submitted>
  <study_first_submitted_qc>June 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2014</study_first_posted>
  <results_first_submitted>December 7, 2020</results_first_submitted>
  <results_first_submitted_qc>August 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 27, 2021</results_first_posted>
  <last_update_submitted>August 28, 2021</last_update_submitted>
  <last_update_submitted_qc>August 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University at Buffalo</investigator_affiliation>
    <investigator_full_name>Thomas Guttuso</investigator_full_name>
    <investigator_title>Associate Professor of Neurology, Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <keyword>pregnancy</keyword>
  <keyword>nausea</keyword>
  <keyword>vomiting</keyword>
  <keyword>hyperemesis</keyword>
  <keyword>treatment</keyword>
  <keyword>gabapentin</keyword>
  <keyword>metoclopramide</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperemesis Gravidarum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 2, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT02163434/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gabapentin</title>
          <description>1800-2400mg/day divided tid or qid, orally.&#xD;
Gabapentin</description>
        </group>
        <group group_id="P2">
          <title>Metoclopramide</title>
          <description>45-60mg/day divided tid or qid, orally&#xD;
Metoclopramide</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gabapentin</title>
          <description>1800-2400mg/day divided tid or qid, orally.&#xD;
Gabapentin</description>
        </group>
        <group group_id="B2">
          <title>Metoclopramide</title>
          <description>45-60mg/day divided tid or qid, orally&#xD;
Metoclopramide</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.2" spread="5.9"/>
                    <measurement group_id="B2" value="26.3" spread="3.9"/>
                    <measurement group_id="B3" value="26.25" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>non-Hispanic white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non-Hispanic black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline Adjusted Mean Daily Motherisk-PUQE Total Scores (Pregnancy-unique Quantification of Emesis and Nausea Scale) for Days 5-7</title>
        <description>Score range: 6-30 with higher score indicating a worse outcome.</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>1800-2400mg/day divided tid or qid, orally.&#xD;
Gabapentin</description>
          </group>
          <group group_id="O2">
            <title>Metoclopramide</title>
            <description>45-60mg/day divided tid or qid, orally&#xD;
Metoclopramide</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Adjusted Mean Daily Motherisk-PUQE Total Scores (Pregnancy-unique Quantification of Emesis and Nausea Scale) for Days 5-7</title>
          <description>Score range: 6-30 with higher score indicating a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.35" spread="2.44"/>
                    <measurement group_id="O2" value="13.22" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Adjusted Mean Daily Nausea Scores From the Motherisk-PUQE for Days 5-7.</title>
        <description>Score range: 2-10 with higher score indicating a worse outcome.</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>1800-2400mg/day divided tid or qid, orally.&#xD;
Gabapentin</description>
          </group>
          <group group_id="O2">
            <title>Metoclopramide</title>
            <description>45-60mg/day divided tid or qid, orally&#xD;
Metoclopramide</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Adjusted Mean Daily Nausea Scores From the Motherisk-PUQE for Days 5-7.</title>
          <description>Score range: 2-10 with higher score indicating a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" spread="0.45"/>
                    <measurement group_id="O2" value="3.69" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Adjusted Mean Daily Oral Nutrition Score for Days 5-7</title>
        <description>Score range: 0-15 with higher score indicating a better outcome.</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>1800-2400mg/day divided tid or qid, orally.&#xD;
Gabapentin</description>
          </group>
          <group group_id="O2">
            <title>Metoclopramide</title>
            <description>45-60mg/day divided tid or qid, orally&#xD;
Metoclopramide</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Adjusted Mean Daily Oral Nutrition Score for Days 5-7</title>
          <description>Score range: 0-15 with higher score indicating a better outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.86" spread="1.23"/>
                    <measurement group_id="O2" value="4.01" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects Requiring Repeat iv Hydration or Hospital Admission for HG From the Outpatient Setting.</title>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>1800-2400mg/day divided tid or qid, orally.&#xD;
Gabapentin</description>
          </group>
          <group group_id="O2">
            <title>Metoclopramide</title>
            <description>45-60mg/day divided tid or qid, orally&#xD;
Metoclopramide</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects Requiring Repeat iv Hydration or Hospital Admission for HG From the Outpatient Setting.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Satisfaction of Treatment at the Study Endpoint.</title>
        <description>Score range: 0-4 with higher score indicating a better outcome.</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>1800-2400mg/day divided tid or qid, orally.&#xD;
Gabapentin</description>
          </group>
          <group group_id="O2">
            <title>Metoclopramide</title>
            <description>45-60mg/day divided tid or qid, orally&#xD;
Metoclopramide</description>
          </group>
        </group_list>
        <measure>
          <title>Global Satisfaction of Treatment at the Study Endpoint.</title>
          <description>Score range: 0-4 with higher score indicating a better outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" spread="1.56"/>
                    <measurement group_id="O2" value="0.63" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Desire to Continue Therapy at Study Endpoint</title>
        <description>Scores: 0=no, 1=yes. Thus, a higher score indicates a better outcome.</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>1800-2400mg/day divided tid or qid, orally.&#xD;
Gabapentin</description>
          </group>
          <group group_id="O2">
            <title>Metoclopramide</title>
            <description>45-60mg/day divided tid or qid, orally&#xD;
Metoclopramide</description>
          </group>
        </group_list>
        <measure>
          <title>Desire to Continue Therapy at Study Endpoint</title>
          <description>Scores: 0=no, 1=yes. Thus, a higher score indicates a better outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.50"/>
                    <measurement group_id="O2" value="0.14" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 week of double-blind therapy</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gabapentin</title>
          <description>1800-2400mg/day divided tid or qid, orally.&#xD;
Gabapentin</description>
        </group>
        <group group_id="E2">
          <title>Metoclopramide</title>
          <description>45-60mg/day divided tid or qid, orally&#xD;
Metoclopramide</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Thomas Guttuso, Jr.</name_or_title>
      <organization>University at Buffalo</organization>
      <phone>7169326080</phone>
      <email>tguttuso@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

